Physician
Gramercy Cardiac Diagnostic Services, P.C.
Gramercy Cardiac Diagnostic Services, P.C. was paid $8.39M by Medicaid between Jan 2018 and Sep 2023, across 34 billing codes. Its largest line is 78492, — 32% of everything it billed.
33Billing provider infoGRAMERCY CARDIAC DIAGNOSTIC SERVICES, P.C.
NEW YORK, NY 10001
NEW YORK, NY 10001
33aNPI1336147859assigned 07/08/2005
33bProvider typeNuclear Cardiology Physician
28Total paid$8.39M
24GClaims45,553
24DCodes billed34
24AFirst – last monthJan 2018 – Sep 2023
Compared with peers
Next to other Nuclear Cardiology Physician providers in New York
Rank by total paid#2 of 56
Median peer was paid$22K
This provider vs. median387×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 8,024 | $1.92M | |
| 2019 | 14,786 | $2.23M | |
| 2020 | 6,822 | $1.29M | |
| 2021 | 11,408 | $2.24M | |
| 2022 | 4,087 | $661K | |
| 2023 | 426 | $51K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 78492 | 32% | 2,194 | 2,186 | $2.70M | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 19% | 4,195 | 4,189 | $1.63M |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 12% | 2,238 | 2,228 | $973K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 7.9% | 3,702 | 3,692 | $659K |
| 93015 | 6.2% | 8,431 | 8,204 | $522K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 4.7% | 3,326 | 3,318 | $391K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.5% | 6,095 | 5,858 | $375K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.9% | 1,783 | 1,781 | $162K |
| J2785 | Injection, regadenoson, 0.1 mg | 1.5% | 668 | 661 | $126K |
| 78431 | 1.5% | 116 | 116 | $124K | |
| 93880 | 1.2% | 695 | 689 | $101K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.1% | 2,269 | 2,175 | $92K |
22 more codes
| 93224 | 1.0% | 1,007 | $86K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 826 | $76K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 374 | $52K |
| 93970 | <1% | 298 | $46K | |
| 93925 | <1% | 282 | $45K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 674 | $38K |
| 93923 | <1% | 309 | $36K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 460 | $31K |
| 93000 | <1% | 1,905 | $27K | |
| 93351 | <1% | 86 | $19K | |
| J1245 | Injection, dipyridamole, per 10 mg | <1% | 2,376 | $19K |
| 99442 | <1% | 244 | $13K | |
| 93922 | <1% | 191 | $12K | |
| 78434 | <1% | 129 | $6K | |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | <1% | 211 | $5K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 208 | $5K |
| 93320 | <1% | 84 | $4K | |
| 99443 | <1% | 34 | $3K | |
| 93975 | <1% | 14 | $3K | |
| 93325 | <1% | 85 | $2K | |
| 93978 | <1% | 12 | $2K | |
| 99441 | <1% | 32 | $1K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMARIN, VICTORIA (PRECERTIFICATION/CREDENTIALS)